NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
National Taiwan University Hospital
Fudan University
The First Hospital of Hebei Medical University
Jacobio Pharmaceuticals Co., Ltd.